Avenue Therapeutics, Inc.

ATXI

US05360L4032

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
3.81 ^USD	+2.14%		-3.54%	-68.45%

May. 16	Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	CI
May. 15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Avenue Therapeutics, Inc. Appoints Lucy Lu as Chief Executive Officer and President

June 02, 2017 at 08:59 am EDT

Avenue Therapeutics, Inc. announced that effective immediately, Lucy Lu, M.D., will serve as Chief Executive Officer and President.

Latest news about Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	May. 16	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	Feb. 22	CI
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Top Midday Gainers	Jan. 04	MT
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study	Jan. 04	DJ
Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	Jan. 02	CI
Maxim Starts Coverage on Avenue Therapeutics with Buy Rating, $0.75 Price Target	Dec. 11	MT
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Insider Buy: Avenue Therapeutics	23-09-12	MT
Avenue Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Fortress Biotech, Inc. and other investor	23-09-07	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study	23-08-01	CI
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	23-07-27	CI
Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol	23-07-25	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
North American Morning Briefing : China Data Helps Support Sentiment	23-04-18	DJ
Avenue Therapeutics Says US FDA Feedback Helps Development of IV Tramadol Study Protocol	23-04-17	MT
Avenue Therapeutics Shares Jump 30% on FDA Meeting Minutes	23-04-17	DJ
Avenue Therapeutics, Inc. Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of Iv Tramadol	23-04-17	CI
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI

Chart Avenue Therapeutics, Inc.

Duration

Period

More charts

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA Î±2, Î±3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.81 USD

Average target price

56.25 USD

Spread / Average Target

+1,376.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AVENUE THERAPEUTICS, INC.	-68.45%	3.51M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs